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Abstract
Background: Serrated adenocarcinoma (SAC) is a recently recognized colorectal cancer (CRC) subtype accounting
for 7.5–8.7 % of CRCs. It has been shown that SAC has a worse prognosis and different histological and molecular
features compared to conventional carcinoma (CC) but, to date, there is no study analysing its methylome profile.
Results: The methylation status of 450,000 CpG sites using the Infinium Human Methylation 450 BeadChip array was
investigated in 103 colorectal specimens, including 39 SACs and 34 matched CCs, from Spanish and Finnish patients.
Microarray data showed a higher representation of morphogenesis-, neurogenesis-, cytoskeleton- and vesicle
transport-related functions and also significant differential methylation of 15 genes, including the iodothyronine
deiodinase DIO3 and the forkhead family transcription factor FOXD2 genes which were validated at the CpG, mRNA
and protein level using pyrosequencing, methylation-specific PCR, quantitative polymerase chain reaction (qPCR) and
immunohistochemistry. A quantification study of the methylation status of CpG sequences in FOXD2 demonstrated a
novel region controlling gene expression. Moreover, differences in these markers were also evident when comparing
SAC with CRC showing molecular and histological features of high-level microsatellite instability.
Conclusions: This methylome study demonstrates distinct epigenetic regulation patterns in SAC which are consistent
to previous expression profile studies and that DIO3 and FOXD2 might be molecular targets for a specific histology-
oriented treatment of CRC.
Keywords: Serrated carcinoma, Colorectal cancer, Methylome, Microarray analysis, FOXD2, DIO3, CpG island,
Pyrosequencing
Background
Serrated adenocarcinoma (SAC) has been accepted in the
latest WHO classification of tumours of the digestive
system as a new subtype of colorectal cancer (CRC) [1].
Criteria for its histologic diagnosis have been proposed [2]
and recently validated in a series of 81 cases [3]. Its fre-
quency ranges from just 7.5 to 8.7 % of all CRCs [2, 3],
but according to 2012 Globocan statistics and given the
high incidence of CRC from all cancers (9.7 %), SAC
would have an incidence similar to that of multiple mye-
loma (0.8 %) (http://globocan.iarc.fr). It has been shown
that SAC has distinct histological and molecular features
and a worse prognosis than conventional carcinoma (CC)
[3]. Accordingly, our group observed that SAC, compared
to CC, displays a higher frequency of adverse histological
features at the invasive front [4] that differs in the expres-
sion pattern of adhesion molecules [5] and oncogene mu-
tation [6]. Additionally, two previous studies on mRNA
profiling have revealed that SAC showed a higher
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representation of morphogenesis-, hypoxia-, cytoskeleton-
and vesicle-transport-related functions and also an
over-expression of HIF-1α, fascin1 (actin-bundling pro-
tein associated with invasion) and the antiapoptotic gene
hippocalcin and a downregulation of the morphogenesis-
related proteins EPHB2 and PTCH [7, 8]. Moreover, SAC
differs from those CRCs displaying histological features of
high-level microsatellite instability (hMSI-H) in terms of
oncogene mutation prevalence, MSI status and MLH1 ex-
pression [6, 8].
A two-arm model has been proposed to explain the
progression of the serrated pathway, both of which
may progress to SAC. Cancers developing from this
pathway may show high- or low-level microsatellite
instability (MSI-H and MSI-L, respectively) or may be
microsatellite stable (MSS) [9]. Sporadic CRC charac-
terized by MSI-H and BRAF mutation displays typical
histological features compared to SAC [10–13] and is
considered a different endpoint of the serrated path-
way [14].
In the serrated pathway, inhibition of apoptosis and
subsequent inactivation of DNA repair genes by pro-
moter methylation appear to play an important role
[1, 2]. Although aberrant cytosine-phospho-guanine
(CpG) methylation has been proposed as the typical
leading mechanism for serrated carcinogenesis [14],
there is no study analysing methylome profiling in
SAC.
In this study, we have analysed the methylome profile
of SAC with the aim of:
 Evaluating the differentially methylated biological
functions of SAC and comparing them with
previous studies including mRNA profiling [7, 8].
 Validating the genes differentially methylated in SAC
in comparison with CC at the CpG, mRNA and
protein level.
 Studying the presence of the identified biomarkers
in hMSI-H and comparing them with those found in
SAC.
Results
As a prerequisite for a matched group, CC did not show
significant differences in terms of demographic and
clinico-pathologic features with SAC in the training and
validation sets included in the study (Table 1).
Differentially methylated functions
Noisy methylation measurements and the high number of
genes tested in the array, which imposes strong p value
corrections, usually hamper the detection of significant
methylation differences at the gene level. As this may be
Table 1 Demographic and pathological features of the study cases
Training set DNA validation set (MSP and
pyroseq)
RNA validation set (qPCR) Protein validation set (IHC)
SAC CC SAC CC SAC CC SAC CC
n = 39 (%) n = 34 (%) p value n = 59 (%) n = 44 (%) p value n = 18 (%) n = 25 (%) p value n = 42 (%) n = 49 (%) p value
Gender
Female 20 (51.3) 16 (47.1) 29 (49.2) 21 (47.7) 8 (44.4) 9 (36.0) 30 (71.4) 28 (57.1)
Male 19 (48.7) 18 (52.9) 0.719 30 (50.8) 23 (52.3) 0.846 10 (55.6) 16 (64.0) 0.5763 12 (28.6) 21 (42.9) 0.157
Age [SD] 71.6 [10.0] 72.3 [7.6] 72.0 [9.5] 70.3 [8.4] 0.348 69.4 [9.8] 72.6 [11.0] 0.331 69.9 [6.8] 70 [10.7] 0.959
Location
Proximal 26 (66.7) 21 (61.8) 34 (57.6) 26 (59.1) 10 (55.6) 14 (56.0) 23 (54.8) 26 (53.1)
Distal /rectum 13 (33.3) 13 (44.1) 0.554 25 (42.3) 18 (40.1) 0.882 8 (44.4) 11 (44.0) 0.977 19 (45.2) 23 (46.9) 0.871
Dukes’ stage
A 4 (10.3) 4 (11.8) 6 (10.2) 4 (9.1) 2 (11.1) 3 (12.0) 7 (16.7) 8 (16.3)
B 13 (33.3) 15 (44.1) 24 (40.7) 18 (40.9) 4 (22.2) 13 (52.0) 15 (35.7) 17 (34.7)
C 17 (43.6) 15 (44.1) 0.875 29 (49.2) 22 (50.0) 0.983 12 (66.7) 9 (36.0) 0.094 20 (47.6) 24 (49.0) 0.992
WHO grade
High 5 (12.8) 2 (5.9) 3 (5.1) 1 (2.3) 0 0 0 2 (4.1)
Low 34 (87.2) 32 (94.1) 0.315 56 (94.9) 43 (97.3) 0.465 18 (100) 25 (100) NA 42 (100) 47 (95.9) 0.186
Type
Non-mucinous 34 (87.1) 30 (88.2) 51 (84.4) 39 (88.6) 16 (88.9) 22 (88.0) 36 (58.7) 41 (83.7)
Mucinous 5 (12.8) 4 (11.8) 0.891 8 (13.6) 5 (11.4) 0.740 2 (11.1) 3 (12.0) 0,929 6 (14.3) 8 (16.3) 0.788
SAC serrated adenocarcinoma, CC conventional carcinoma, MSP methylation-specific PCR, CpG pyroseq CpG island pyrosequecing, qPCR quantitative polymerase
chain reaction, IHC immunohistochemistry, SD standard deviation, WHO World Health Organisation
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the case in our study, we opted for an alternative, yet well-
established approach to identify regulated functions in
high “omics” experiments, namely the Gene Set Enrich-
ment Analysis approach (GSEA) which relies on the or-
dering of genes according to a molecular phenotype, as
differential expression or methylation, rather than on a
gene selection based on a pre-defined p value cutoff. We
used the GSEA-related method Fatiscan [8] to analyse our
data. This approach revealed a considerable number of
GO terms differentially methylated in SAC vs. CC: 86 GO
biological processes (BP), 31 GO CC and 69 GO mole-
cular functions (MF). Differentially methylated activities
were related to ion binding, intracellular transport, actin
binding, GTPases and kinase signaling, neural markers,
DNA repair and VEGF signaling amongst others. Figure 1
shows the FatiScan annotated function corresponding to
the GO biological process and molecular functions, and
Additional file 1 represents box plots indicating the
Fig. 1 GO plots representing significant Gene Ontology biological process a and molecular functions b differentially methylated in SAC
compared to CC. Each node shows a significant function and its size the grade of significance. Red contours around the nodes indicate that this
function is more represented in SAC whereas blue signifies CC. Nodes are grouped in clusters showing similar functions. The number for each
cluster shows the amount of unique genes for this cluster. The different functions were grouped according to the concordance Kappa value
based on the number of shared genes between functions (only lines representing a Kappa > 0.2 are depicted and line thickness indicates higher
Kappa)
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number and the percentage of genes belonging to each of
these functions. Additional file 2 shows the GO plots and
box plots corresponding to the GO cellular component
category. In contrast, only 7 GO biological processes, 8
cellular components and 11 molecular functions were dif-
ferentially methylated when comparing Spanish SAC and
Finnish SAC tumour cases (data not shown).
Differentially methylated genes
The analysis of the methylome microarray data identified
15 differentially methylated genes, 14 of which were more
methylated in SAC than in CC (Table 2). No significant
methylated genes were observed when comparing normal
SAC and CC mucosa or Spanish and Finnish serrated
cases.
The differentially methylated genes that we found encode
transcription factors (FOXD2), kinases (RIOK3), G protein-
coupled receptor and GTPases (OR4N5, OR51G1, LRRK2)
which are involved in hormone regulation (DIO3), cytoskel-
eton and vesicle transport (RIOK3, WASF3, ATP6V1C1),
apoptosis (XKR4), morphogenesis (FOXD2), regulation of
nervous cells (FAM19AS, QPRT) and telomere mainten-
ance (POT1) amongst others (Table 2).
Validation of methylated sites by MSP and
pyrosequencing
Based on the extent of the differential methylation grade,
the importance of the biological functions, the design of
suitable primers and the availability of antibodies, we de-
cided to validate DIO3 and FOXD2 by methylation-
specific PCR (MSP) and pyrosequencing, respectively,
and by quantitative polymerase chain reaction (qPCR)
and immunohistochemistry (IHC) for both. As regards
the first two, the distribution of CpG sites and the flank-
ing sequence of the DIO3 and FOXD2 CpG islands make
the validation by MSP more feasible in the case of DIO3
(CpG sites more condensed) and by pyrosequencing in
the case of FOXD2 (CpGs more scattered).
Consistent with the microarray results, MSP re-
vealed that DIO3 CpGs were more methylated in
SAC than in CC cases (36/59, 61.1 vs. 14/44, 31.8 %;
p = 0.003), Additional file 3 showing representative re-
sults. When the correlation of DIO3 methylation was
evaluated with oncogene mutation and MSI status, no
significant associations were found (data not shown)
except for a tendency of BRAF mutation with DIO3
methylation (BRAF mutated, 10/13 (79.9 %) vs. BRAF
WT, 24/51 (47.1 %); p = 0.054).
Table 2 Differentially methylated genes between serrated adenocarcinoma and conventional carcinoma obtained from the
methylome analysis
Symbol Gene name and protein function > meth in: Fold change Raw p value Adj. p value
DIO3 Type III iodothyronine deiodinase. Inactivation of
thyroid hormone
SAC 209.939.101.331.552 7.41E+05 0.0001
FOXD2 Forkhead box protein D2. Transcription factor SAC 0.889154808110723 7.14E+07 0.0066
OR4N5 Olfactory receptor, family 4, subfamily N, member 5.
G protein-coupled receptor
SAC 135.181.723.252.813 8.99E+08 0.0452
RIOK3 RIO kinase 3. Cytoskeleton rearrangement SAC 0.635422579240145 9.83E+08 0.0452
WASF3/WAVE3 Wiskott-Aldrich syndrome protein family, member 3.
Cytoskeleton rearrangement
SAC 120.522.262.330.085 1.38E+09 0.0467
OR51G1 Olfactory receptor, family 51, subfamily G, member 1.
G protein-coupled receptor
SAC 168.046.340.201.344 1.81E+09 0.0467
BPIFA2/SPLUNC2 Short palate, lung and nasal epithelium carcinoma
associated 2. Lipopolysaccharide binding
SAC 0.911123350424225 2.24E+09 0.0467
ATP6V1C1 ATPase, H+ transporting, lysosomal 42 kDa, V1 subunit
C1. Intracellular protein sorting and endocytosis
SAC 160.360.515.634.696 2.29E+09 0.0467
NIPAL4 NIPA-like domain containing 4. Membrane receptor SAC 153.320.826.961.118 2.67E+09 0.0467
LRRK2 Leucine-rich repeat kinase 2. GTPase and kinase SAC 170.637.559.235.708 2.72E+09 0.0467
QPRT Quinolinate phosphoribosyltransferase. Catabolism of
endogenous excitotoxin to neurons
CC −0.698324044955379 3.28E+09 0.0467
PRR5 Proline rich 5 (renal). mTOR pathway SAC 0.892188635181469 3.63E+09 0.0467
XKR4 Kell blood group complex subunit-related family,
member 4. Apoptosis
SAC 0.737099384900948 3.66E+09 0.0467
FAM19A5 Family with sequence similarity 19 (chemokine (C-C
motif)-like), A5. Regulation of immune and nervous cells
SAC 0.734137349204086 3.69E+09 0.0467
POT1 protection of telomeres 1. Telomere maintenance SAC 0.551207360675112 3.81E+08 0.0467
SAC serrated adenocarcinoma, CC conventional carcinoma, > meth in CRC subtype showing higher methylation for that gene
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Concerning FOXD2, CpG sequence analysis revealed
three different clusters of CpG sites, two in the 5′ UTR
and one in the 3′ UTR. From these three regions, only
the 3′ UTR, which comprised nine CpG sites, was found
to be substantially methylated (Fig. 2a). The mean and
SD of the methylation percentage for each CpG site and
study group is shown in Additional file 1. Interestingly,
normal tumour-adjacent mucosa showed a lower per-
centage of methylation (mean = 31.19) than the tumoural
group (mean = 52.81), this difference being statistically
significant (F (1.106) = 28.636, p < 0.001, partial = 0.213).
The non-tumoural cases had a more similar methylation
pattern than the tumoural cases (Levene’s F > 16, p < 0.001)
(Additional file 4A).
Figure 3 and Additional file 3 show that SAC displays
a higher percentage of methylation compared to that
observed for CC in each of the nine CpG sites, although
not reaching statistical significance. In order to test
which variable was associated with higher FOXD2
methylation, a bivariate analysis was performed. Higher
FOXD2 methylation was associated with tumoural speci-
mens, KRAS, BRAF and exon 20 PIK3CA mutation and
MSI-H status (Table 3). Therefore, specimen status,
KRAS, BRAF and MSI were used as predictors for the
multivariate analysis whereas exon 20 PIK3CA mutation
was excluded as the sample size was less than 15.
Additional file 5 indicates that only tumoural status and
MSI remained significant independent predictors. For
the normal and MSS cases, the model predicts a 32.8 %
occurrence of methylation in R3 with an increase of 17.1
points for tumoural cases and 13.7 for MSI cases. More-
over, external validation with the TCGA database was
Fig. 2 Mean percentage of the different CpG sites found in the first (4 sites) and second (11 sites) 5′ UTR and in the 3′ UTR regions of FOXD2 (a).
Correlation graphic between the methylation percentage of FOXD2 3′ UTR CpG sites and FOXD2 mRNA expression by qPCR (b)
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also successful showing that MSI-H expressed less
FOXD2 than MSI-L/MSS colon carcinomas (p = 0.001)
(Additional file 6).
Validation by qPCR
With the aim of finding out whether the DIO3 and
FOXD2 hypermethylation affected gene activation, an ana-
lysis of the mRNA expression by quantitative PCR was
performed. As shown in Table 4, all the compared me-
dians were significantly different. The tumoural and non-
tumoural groups differed in the expression of DIO3 and
FOXD2, the non-tumoural group showing a lower median
for both variables (0.154 ± 0.18 vs. 0.054 ± 0.134; p = 0.043
and 0.281 ± 0.473 vs. 0.095 ± 0.301; p = 0.013, respectively,
Additional file 4B). Amongst tumoural cases, SAC
displayed lower expression medians than CC for both
genes (DIO3, 0.007 ± 0.095 vs. 0.131 ± 0.155; p = 0.02 and
FOXD2, 0.01 ± 0.253 vs. 0.174 ± 0.331; p = 0.041) (Fig. 4).
Additionally, a positive relationship between DIO3 and
FOXD2 expression was observed. For the whole group
(tumoural and non-tumoural, serrated and conventional),
Pearson’s correlation coefficient was r = 0.792 (p < 0.001,
n = 52); this value indicating that the expression of both
genes shares almost 63 % of their variance (R2 = 0.627). If
we consider only the tumoural cases, it was r = 0.751 (p <
0.001, n = 43), both genes sharing 56 % of their variance
(R2 = 0.564) (Additional file 6). In fact, CRC data de-
posited in the TCGA data sets confirmed this direct
correlation as significant (p = 0.037) [15] as retrieved
via www.cbioportal.org.
In order to test if 3′ UTR FOXD2 CpG sites might be
regulating FOXD2 expression, we performed a
Fig. 3 Mean methylation percentages of the nine CpG sites of the 3′UTR region of FOXD2 in the different study groups
Table 3 Differences in percentage of methylation in FOXD2 3′ UTR for the two groups defined with each binary variable
Variable n1 n2 Mean1 Mean2 Eequal variances Difference (1–2) gl t p values
Source 31 normal 90 tumoural 32.35 52.69 No −20.35 112 −7.094 <0.001
Nationality 98 Spanish 23 Finnish 47.62 46.89 No 0.72 29 .128 0.899
Sex 32 female 59 male 47.98 46.96 Yes 1.02 119 .262 0.794
Ma 106 0 s 12 1 s 47.38 50.69 Yes −3.31 116 −.517 0.606
KRAS 85 native 34 mutated 44.89 53.74 Yes −8.85 117 −2.095 0.038
BRAF 100 native 18 mutated 44.93 62.11 No −17.18 48 −5.247 <0.001
PI3K exon10a 90 native 5 mutated 46.91 58.55 Yes −11.65 93 −1.254 0.213
PI3K exon20a 92 native 3 mutated 46.91 66.37 No −19.47 3 −3.692 0.038
MSI 102 MSS 16 MSI 44.65 63.58 No −18.93 70 −6.887 <0.001
aWhen the sample size is <15 in any of the groups, t test should not be interpreted. The Mann-Whitney’s U test was used for the variables M, PI3K exon10 and
PI3K exon20. No significant differences were found for any of them
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Spearman’s correlation analysis which showed that all
these sites revealed negative r values indicating an in-
verse relationship between methylation and mRNA ex-
pression and statistically significant correlations except
for CpG2 (p < 0.01) and CpG9 sites (p = 0.084). This
finding was also observed when representing the mean
of the methylation of the nine CpG positions with the
qPCR results (Fig. 2b, Additional file 7).
Validation by immunohistochemistry
In order to investigate whether differential methylated
status of DIO3 and FOXD2 in SAC compared to CC
could have an effect on protein expression within the
tissue cells, immunohistochemistry for both D3 and
FOXD2 was performed. Both markers showed a granular
cytoplasmic staining which was more evident at the lu-
minal border (Fig. 5). Whereas no significant differences
were observed in the staining distribution of D3 when
SAC vs. CC were compared, FOXD2 staining was more
diffuse in SAC (p = 0.013) (Table 5). In addition, SAC
showed higher D3 and FOXD2 intensity staining than
CC (p = 0.051, p = 0.054), being statistically significant
when strong intensity was compared to combined weak
and moderate staining (D3, 45.2 vs. 22.4 %; p = 0.018,
FOXD2, 54.8 vs. 30.6 %; p = 0.020).
Biomarker comparison between SAC and hMSI-H
As shown in Fig. 3, hMSI-H tumour cases were more
methylated in FOXD2 than SAC and CC which was not
unexpected since the MSI-H feature was associated with,
and was an independent factor for, FOXD2 methylation
(Table 3, Additional file 5). Consequently, qPCR analysis
revealed that FOXD2 expression was less in hMSI-H
than that in SAC (p = 0.030) or CC (p < 0.001) and that
of DIO3 less in hMSI-H than that in CC (p = 0.002) but
without reaching statistical significance in the compari-
son with SAC (p = 0.243) (Table 4). Interestingly, immu-
nohistochemical analysis revealed that hMSI-H showed
less D3 and FOXD2 expression than SAC and CC, both
in staining distribution and intensity, especially for
FOXD2 (Table 5; Fig. 4)
Table 4 DIO3 and FOXD2 mRNA expression assessed by quantitative PCR
Tumoural cases All cases
SAC CC hMSI-H Non-tumoural Tumoural
n 18 25 8 9 43
Median ± SD 0.007 ± 0.095 0.131 ± 0.155 0.0021424 ± 0.008 0.154 ± 0.18 0.054 ± 0.138
DIO3 Mann-Whit. U 131 51a/29b 110
p 0.020 0.243a/0.002b 0.043
Median ± SD 0.01 ± 0.253 0.174 ± 0.331 0.0007 ± 0.003 0.281 ± 0.473 0.095 ± 0.301
FOXD2 Mann-Whit. U 142 33a/7b 91
p 0.041 0.031a/<0.001b 0.013
SAC Serrated adenocarcinoma, CC Conventional carcinoma, hMSI-H colorectal carcinoma showing typical molecular and histological features of MSI-H
aSAC vs. hMSI-H comparison; bCC vs. hMSI-H comparison
Fig. 4 qPCR results of the mRNA expression of DIO3 and FOXD2 genes in SAC, CC, and hMSI-H tumoural tissue. Asterisk indicates statistical
significance
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Discussion
Altered methylation patterns not only serve as important
diagnostic and prognostic markers but are also aetiological
factors in colonic carcinogenesis [16]. Whereas the patho-
genic sequence leading to conventional carcinoma has
been extensively studied, the molecular events responsible
for the serrated pathway are poorly understood. SAC is
considered as one endpoint of the serrated pathway and,
since its recognition by the WHO as a different CRC en-
tity, several studies have aimed to characterize it [2–8]. O’
Brien et al. investigated the methylation status of five
genes (hMLH1, MGMT, MINT1, MINT2, p16) compris-
ing the so-called CpG-island methylation phenotype
(CIMP) in serrated carcinomas and precursor polyps [17]
and found that higher CIMP levels (four or more markers
positive) were significantly more frequent in advanced
Fig. 5 Immunohistochemical expression of D3 and FOXD2 in SAC (a, b), CC (c, d), hMSI-H (e, f), and normal mucosa including an adenoma area
in the upper left corner (g, h). ×20 magnification and H-E counterstained
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stages of the serrated pathway. However, no previous
studies have analysed the SAC methylome by means of
high-throughput techniques.
Our study suggests that SAC shows differential methyl-
ated functions and genes compared to CC and, moreover,
the 186 GO differentially methylated functions found are
consistent with previously reported differentially expressed
functions (GTPases, cytoskeleton, morphogenesis, apop-
tosis, vesicle transport and neuronal regulation functions)
obtained from two microarray studies comparing the
mRNA profile of 5 [7] and 11 [8] SACs with that of CCs. In
addition, these functions are also supported by different
studies characterizing the histological, immunohistochemi-
cal and molecular features of SAC [3–6, 12]. Noteworthy,
Spanish and Finnish SAC cases only showed 26 diffe-
rentially methylated GO functions and no differentially
methylated gene, thus supporting the criteria for its diagno-
sis [11] and for a common pathogenic mechanism despite
the differences in environmental and genetic background.
As regards the differentially methylated genes, it is im-
portant to emphasize that none were observed in the
comparison of non-tumoural SAC vs. matched non-
tumoural CC, therefore supporting the absence of a dis-
tinct and relevant baseline methylation alteration. The
comparison between SAC and CC showed 15 genes dif-
ferentially methylated, 14 of which were more methyl-
ated in SAC, thus highlighting the involvement of
aberrant methylation in SAC compared to CC. In fact,
SAC, in comparison to CC, was more frequently CIMP
high than CC (11/37, 30 % vs. 3/32, 9 %; p = 0.0035)
(unpublished observations). The differentially methylated
genes found are consistent with the functions previously
assigned to SAC in microarrays studies [7, 8] like GTPase
activity (OR51G1 and LRRK2), cytoskeleton (RIOK3 and
WASF3), vesicle transport (ATP6V1C1), mTOR pathway
(PRR5), apoptosis (XKR4), membrane-associated functions
(NIPAL4 and DIO3), morphogenesis (DIO3 and FOXD2),
immune response (FAM19A5 and WASF3) and neural
markers (QPRT).
The only gene more methylated in CC than in SAC
was QPRT which codes for an enzyme that was found to
detoxify quinolinate, a potent endogenous neuron toxin
that is elevated in the brain of patients with neurodegen-
erative disorders such as Alzheimer's disease [18]. In this
respect, previous studies from our group reported the
differential expression of neural regulation processes and
the upregulation of specific genes such as hippocalcin,
a sensor protein that participates in preventing the
calcium-driven apoptosis in neurons, of SAC compared to
CC [8]. Therefore, this finding suggests that SAC tumoral
cells use neuroprotective mechanisms to prevent apop-
tosis, a common hallmark of this tumour which is respon-
sible for its saw-shaped growth pattern. The validation of
DIO3 and FOXD2 at the DNA, mRNA and protein level
was carried out based on its level of significance, CpG site
distribution and reagent availability. The MSP study con-
firmed that DIO3 was more methylated in SAC than in
CC, and qPCR confirmed that this might result in a de-
crease in the mRNA level of expression. DIO3 protein,
also known as D3, is the type 3 deiodinase which inacti-
vates the tissue effects of thyroid hormones, these playing
a pivotal role in the regulation of cell proliferation and
morphogenesis of the intestine as observed in animal
models [19]. In fact, D3 is elevated in various colon cancer
cell lines as well as in human colorectal cancer tissues
compared to their normal counterparts and its expression
Table 5 Immunohistochemical expression of D3 and FOXD2 proteins in SAC, CC and hMSI-H CRC
SAC (n = 42) CC (n = 49) hMSI-H (n = 13)
Protein n n % n % p value n % p value†
D3 distribution A 7 16,7 8 16,3 0 0,0
B 8 19,0 16 32,7 0.144* 1 7,7 0.049*
C 27 64,3 25 51,0 0.313 12 92,3 0.132
intensity 1 11 26,2 22 44,9 7 53,8
2 12 28,6 16 32,7 0.018* 5 38,5 0.013*
3 19 45,2 11 22,4 0.051 1 7,7 0.039
FOXD2 distribution A 0 0,0 6 12,2 7 53,8
B 6 14,3 13 26,5 0.008* 3 23,1 <0.0001*
C 36 85,7 30 61,2 0.013 3 23,1 <0.0001
intensity 1 2 4,8 2 4,1 11 84,6
2 17 40,5 32 65,3 0.02* 2 15,4 0.0005*
3 23 54,8 15 30,6 0.054 0 0,0 <0.0001
SAC Serrated adenocarcinoma, CC Conventional carcinoma, hMSI-H colorectal carcinoma showing typical molecular and histological features of MSI-H
*Fisher p value calculated when grouping the first two categories, i.e. A + B or 1 + 2
†SAC vs. hMSI-H comparison
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is a result of the canonical Wnt/β-catenin pathway activa-
tion [20]. Therefore, the less-methylated status and the in-
creased expression of DIO3 in CC cases suggest an
involvement of D3 in the downstream transcriptional ef-
fects of β-catenin which characterize the CC, but not the
SAC carcinogenic process. As opposed to CC, nuclear β-
catenin is not expressed in the tumour invasive front [6],
nor it also observed in a serrated mice model [21], thus
suggesting a lack of implication of this protein in the
epithelial-mesenchymal transition in SAC. Other reports
have demonstrated that D3, under the control of the Sonic
Hedgehog (Shh) pathway, promotes cell proliferation in
basal cell carcinomas [22]. Interestingly, whereas the in-
crease in DIO3 methylation in SAC was confirmed with
decreasing mRNA expression, the IHC study revealed a
higher intensity cytoplasmic staining of D3 in this type of
tumour compared to CC. D3 is an integral membrane
protein most of which is extracellular thus allowing ready
access to circulating thyroid hormones. It has been re-
ported that the way it is inactivated is by internalization
from plasma membrane to early endosomes [23]. The
granular cytoplasmic staining observed in our immuno-
histochemical experiments could suggest a negative feed-
back mechanism of methylation-driven silencing of DIO3
gene when D3 accumulates in the cytoplasm or alternative
mRNA transcripts which may not be regulated by this
CpG methylation. Possible impairment of D3 trafficking
to the membrane or accelerated internalization in SAC
could be responsible for this observation. In fact, vesicle
transport and cytoskeleton are amongst the differentially
expressed functions obtained from the comparison be-
tween SAC and CC.
Much less is known about FOXD2, a member of the
family of the well-conserved winged helix forkhead tran-
scriptional factors. Previous reports in animal models
have demonstrated a role for it in morphogenesis, pos-
sibly through Shh signaling [24], and in regulating sensi-
tivity to cAMP in T lymphocytes [25]. Noteworthy, the
only two studies of FOXD2 in humans are related to
cancer; in one, a locus including the FOXD2 was found
to be deleted in meningioma [26] and, in the other, the
protein was found to be more highly expressed in pros-
tate cancer and lymph node metastases compared to
normal prostate [27]. In our study, we validated the
microarray result by qPCR showing that FOXD2 was
less expressed in SAC than in CC. By quantifying the
relative methylation of FOXD2 CpG island, there was a
consistent trend although not reaching statistical signifi-
cance. Nevertheless, we observed that a region of the 3′
UTR, but not 5′ UTR, appears to be involved in the
control of FOXD2 expression and, in fact, we have
shown that methylation in this region is strongly corre-
lated with decreased mRNA expression. Moreover, this
FOXD2 methylation is related to microsatellite instability,
thus the reason why the methylation results did not reach
significance as there were MSS CRCs amongst SAC cases.
Differences on FOXD2 RNA expression are more pro-
found and consistent than those observed in its methyla-
tion, thus suggesting that additional factors to methylation
such gene deletion could be influencing FOXD2 expres-
sion. Interestingly, FOXD2 maps to chromosome 1p32-34,
a locus frequently deleted in the serrated pathway [28].
Whether FOXD2 could be acting as a tumour suppressor
gene in MSI-H CRC deserves future studies. FOXD2
showed an increased cytoplasmic expression in SAC com-
pared to CC and, despite being a transcriptional factor, it
was not detected in the nucleus of any cases. Hence, as
with D3, a negative feedback of cytoplasmic FOXD2 on
gene silencing may be implicated. It is important to stress
that protein expression assessed by immunohistochemis-
try does not give information on protein functionality or
isoform type. The increased staining of D3 and FOXD2
could be a result of the translation of alternative gene
transcripts with a different regulation and stability. In this
context, the positive correlation observed between DIO3
and FOXD2 expression and prior evidence of the partici-
pation of these two proteins in the Shh pathway might
justify a common behaviour in protein expression and
functionality. In fact, according to TCGA database, DIO3
expression is associated with only 12 genes, FOXD2 being
one of them [15].
Our results also show that SAC and hMSI-H are dif-
ferent CRC entities, the latter showing a higher FOXD2
methylation percentage and lower FOXD2 mRNA ex-
pression. The immunohistochemical study showed that
hMSI-H, as opposed to SAC, displayed a significant lack
of staining for both D3 and FOXD2, thus suggesting a
direct effect of methylation upon protein expression and
highlighting further molecular differences between these
two histological CRC subtypes considered as two end-
points of the serrated pathway.
Conclusions
– SAC and CC are different CRC in terms of
methylated functions, thus reinforcing the concept
that SAC is characterized by distinct defects in the
regulation of morphogenesis, apoptosis, neural
markers and Wnt/β-catenin pathway activation.
– DIO3 and FOXD2 are two novel genes that are
differentially methylated and expressed in CC, SAC
and another endpoint of the serrated polyps
pathway as it is the CRC showing molecular and
histology features of MSI-H, and thus, they may
serve as novel interesting diagnostic markers,
pathogenic routes tracers or molecular targets.
– This study also reports for the first time the
association of FOXD2 methylation with CRC
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development and shows which CpGs seem to be
involved in gene expression regulation.
Methods
Patients and tumour samples
The clinico-pathological features of the patients have
been previously reported [3, 4]. Approval for the study
was granted by the Santa Lucia University Hospital Eth-
ical Board, and informed consent was obtained from the
patients. SACs were diagnosed on the basis of prior
established criteria (epithelial serrations, clear or eosino-
philic cytoplasm, abundant cytoplasm, vesicular nuclei,
absence of, or less than 10 % necrosis of the total surface
area, mucin production and cell balls and papillary rods
in mucinous areas of a tumour [2]) and so for CCs [13].
Frozen samples of 39 SACs were retrieved from the
Santa Lucia University Hospital, Cartagena Spain (n =
21) and the Oulu University, Finland (n = 18) for CpG
methylation profiling and, in addition, adjacent normal
mucosa was analysed from 16 SACs (12 Spanish and
four Finnish cases). A control group of 34 CCs frozen
samples matched with SACs for gender, age, location,
Dukes’ stage, WHO grade and mucinous pattern was se-
lected from the same tumour banks (25 Spanish and
nine Finnish cases) accompanied by mucosal tissue in 14
of these (10 Spanish and 4 Finnish). MSI-H was present
in 20 % and 2.9 % of SAC and CC cases, respectively.
The mutation rate in KRAS and BRAF oncogenes, which
was previously assessed [6], was 48.5 and 3 % for CC,
33.3 and 33.3 % for SAC and 11.1 and 66.7 % for hMSI-
H, respectively. Validation by qPCR was performed on
the methylome series and on an additional set of 24
SACs and 12 CCs frozen tumour cases. Paraffin blocks
of 42 SAC and 49 CC cases, included in previous studies
[6, 8], were used for immunohistochemical validation of
the microarray results. Clinico-pathological features of
the cases are shown in Table 1. Additionally, a previously
described series of 13 CRCs [6, 8] showing MSI-H mo-
lecular and histological features (mucinous, signet-ring
cell, and medullary carcinoma, tumour infiltrating and
peritumoural lymphocytes, “Crohn-like” inflammatory re-
sponse, poor differentiation, tumour heterogeneity and
“pushing” tumour border [10]) termed hMSI-H were also
studied. These hMSI-H were found mostly in females
(69.2 %), mean age 70.5 (±10.0), located in proximal colon,
showing Dukes’ B (38.5 %) and C (61.5 %) stage, morpho-
logical WHO low grade and 15.4 % displaying a mucinous
pattern in more than 50 % of the tumour. MSI status was
previously determined, according to the manufacturer’s
instructions, in all CRC cases using the MSI Analysis Sys-
tem, version 1.2 provided by Promega (Madison, USA)
which includes fluorescence-labeled primers for co-
amplification of seven markers including five mononucle-
otide repeat markers (BAT-25, BAT-26, NR-21, NR-24
and MONO-27) and two pentanucleotide ones (Penta C
and Penta D) [6].
DNA extraction
A volume of approximately 10 mm3 was extracted from
each frozen tissue using the disposable sterile biopsy
punch. DNA was extracted following the manufacturer’s
instructions (QIAGEN, Hilden, Germany). Briefly, tissue
was disrupted and homogenized in ATL buffer using a
Tissueruptor (QIAGEN) incubated with proteinase K,
and the homogenate was subjected to automatic DNA
extraction using the Qiacube equipment and the
QiaAmp DNA Mini Kit (cat n°:51306), both provided by
QIAGEN.
Bisulfite treatment and DNA methylation assay
HumanMethylation450K BeadChip (Illumina, Inc., San
Diego, CA), using Infinium HD Methylation assay for
genome-wide DNA methylation screening, was employed.
In brief, genomic DNA (1000 ng) from each sample was
bisulfite converted with the EZ DNA Methylation Kit
(Zymo Research, Orange, CA) according to the manu-
facturer’s recommendations. Bisulfite-treated DNA was
isothermally amplified at 37 °C (20–24 h), and the DNA
product was fragmented by an endpoint enzymatic
process, then precipitated, resuspended, applied to an
Infinium Human Methylation450K BeadChip (Illumina,
San Diego, CA, USA) and hybridized at 48 °C (16–24 h).
The fluorescently stained chip was imaged by the Illu-
mina i-SCAN and Illumina’s Genome Studio program
(Methylation Module) was used to analyse BeadArray
data to assign site-specific DNA methylation β values
to each CpG site.
Preprocessing of Methylation data
Processing of raw data was done using R packages. Probes
with a low detection p value (p < 0.01) in more than 95 %
of the samples and those measuring SNPs or mapping in
X or Y chromosomes were removed and normalization
followed a three-step procedure. Firstly, a colour bias ad-
justment was applied using the methylumi R-package [29].
Then, wateRmelon [30] R-package was used to perform
between-sample normalization by equalization of type I
and type II backgrounds followed by separated quantile
normalization of methylated and unmethylated intensities.
Finally, A BMIQ [31] intra-sample normalization proced-
ure, included in the wateRmelon R-package, was applied
to correct the bias of type II probe values.
Functional profiling
Functional profiling of the differentially methylated
genes was performed using the FatiScan method in-
cluded in the Babelomics [32, 33] web suite. The
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Gene Ontology (GO) [34] database was used in this
functional profiling analysis.
Results of functional profiling were represented by two
graphs for each considered GO category: biological process,
molecular function and cellular component. Significant GO
terms of each category are clustered applying hclust func-
tion included on R [35], using Cohen’s kappa value [36] as
a measure of the similarity between two terms. This value
measures the agreement between two GO terms as regards
shared and exclusive items between them.
Differential methylation analysis
The analysis of differentially methylated genes was per-
formed using limma [32] R-package. Data were fitted to
a linear model and differential methylated genes were
identified by using the empirical Bayes method included
in the package. If the comparison was done between
paired samples, a moderated paired t test was applied. A
FDR-corrected p value of 0.05 was used as the threshold
to select differentially methylated genes.
MSP
Converted DNA from the study cases was subjected
to MSP CpG islands analysis. Information on primer
sequences and annealing temperatures is provided as
Additional file 3. After amplification, PCR products were
subjected to electrophoresis using the QIAxcel equipment
and the QIAxcel DNA High Resolution Cartridge (ref:
929002, QIAGEN, Hilden, Germany).
Pyrosequencing
DNA methylation signatures of three different CpG island
regions were analysed and quantified using pyrosequenc-
ing. Details of primer sequences and PCR are provided in
Additional file 3. PCR products were verified using the
QIAxcel DNA high-resolution electrophoresis system.
Pyrosequencing of methylated sites was performed using
the PyroMark Q24 (QIAGEN) according to the manufac-
turer’s protocol. The methylation level was assessed using
the PyroMark Q24 2.0.6 Software (QIAGEN) by which
the methylation percentage (mC/mC+C) for each CpG
was calculated. The results are presented as the percent-
age (mean ± SD) of the different CpG sites studied for
each of the three regions analysed whose sequences
and relative positions are shown as Additional file 7.
Quantitative PCR for assessing mRNA expression
RNAs from 18 SACs and 25 CCs, including those from
the training set, were extracted with the miRNeasy kit
(ref:217004, QIAGEN) and used for validation by qPCR.
The retrotranscriptase reaction was performed from a
total of 1 μg of DNAseI-treated RNA using the Dy-
NAmo cDNA synthesis Kit (ref:F470L) provided by
Thermo Scientific (Rockford, IL), and information on
the qPCR experiment is provided as Additional file 3.
The relative quantitation was done by the 2-ΔCt method
using β-actin as the housekeeping gene.
Immunohistochemistry
The validation subset consisted of 63 SC and 64 CC
cases matched for gender, age and location, and a repre-
sentative area of each tumour was selected by one of us
(JGS) for a tissue microarray (TMA) construction as
previously described [5]. Details on the immunohisto-
chemistry procedure are provided as Additional file 3.
TMA sections of 2.5 μm were stained with anti-D3
and anti-FOXD2 antibodies after confirming a homoge-
neous tumour cell staining in whole tissue sections.
These markers were evaluated by considering a staining
intensity (1 = none or weak staining, 2 =moderate, 3 =
strong) and a staining area score (A < one third, B =
between one and two thirds, C > two thirds) in a given
area. For statistical analysis, both intensity and distribution
were considered.
Statistical analysis of validation data
For the analysis of quantification of methylated DNA se-
quences, the data correspond to a split-plot design with
one between-subject factor defining six independent
groups of cases (SAC, CC, hMSI-H; tumoural and non-
tumoural) and one within-subject factor (CpG sites)
defining nine repeated measures for every case. Accord-
ingly, we performed two ANOVA SPF-p-q. The first
compared the means of the tumoural vs. non-tumoural
groups in each of the nine different CpG sites, and the
second the means of the six different groups in these
sites. For checking the relationship between methylation
percentage and binary variables, the t test for independ-
ent samples and the Mann-Whitney’s U test were used.
Statistical significance in the immunohistochemistry
study was assessed using Pearson χ2 or Fisher´s exact
test when indicated. Descriptive statistics were com-
puted for real-time PCR. External validation of FOXD2
expression and DIO3-FOXD2 correlation was performed
using the TCGA database for colon carcinomas (n = 324)
[15]. Statistical analysis was performed using the SPSS
(Version 22, Chicago, IL) package.
Availability of supporting data
The data set supporting the results of this article are
available in the GEO repository, GSE68060 in http://
www.ncbi.nlm.nih.gov/geo/info/linking.html.
Additional files
Additional file 1: Box plots representing the GO biological process
(A) and molecular functions (B) differentially methylated between
SAC and CC. Each colour indicates functions belonging to the same
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cluster, bar length the number of genes mapping this function and the
percentage their contribution to the total of genes included in the
function.
Additional file 2: Significant Gene Ontology cellular components
differentially methylated between SAC and CC. In the GOplot (A),
each node shows a significant function and its size the grade of
significance. Red contours around the nodes indicate that this function is
more represented in SAC whereas blue signify CC. Nodes are grouped in
clusters showing similar functions. The number for each cluster shows
the amount of unique genes for this cluster. The different functions are
grouped according to the concordance Kappa value based on the
number of shared genes between functions (only lines representing a
Kappa > 0.2 are depicted and line thickness indicates higher Kappa). In
the box plot (B), each colour indicates the functions belonging to the
same cluster. Bar length represents the number of genes mapping this
function, and the percentage indicates the contribution of these genes
to the total of genes included in the GO function.
Additional file 3: Primer sequences used and PCR conditions for
the validation by MSP (including a representative result), CpG
pyrosequencing (including the result table), quantitative PCR and
details on immunohistochemistry and statistical analysis.
Additional file 4: Comparison of non-tumoural compared to
tumoural cases in terms of methylation percentage of the nine
CpGs at the 3′ UTR FOXD2 region (A) and mRNA DIO3 and FOXD2
expression (B). Note the different standard deviation from these two
groups in A. Asterisk indicates statistical significance.
Additional file 5: Multivariate analysis of the clinicopathological
and molecular factors associated with FOXD2 methylation (A); DIO3
and FOXD2 mRNA expression in hMSI-H tumoural and normal
specimens (B) and external validation using TCGA database
showing that MSI-H expressed less FOXD2 than MSI-L/MSS colon
carcinomas (C).
Additional file 6: Positive correlation between mRNA expression of
DIO3 and FOXD2 in both non-tumoural and tumoural tissues.
Additional file 7: Distribution of the CpG sites studied in the FOXD2
gene and correlation table of the methylation percentages at the 3´
UTR CpG sites with FOXD2 mRNA expression.
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